Wanbury Limited

WANBURY

INE107F01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:54 28/06/2024 pm IST			5-day change	1st Jan Change
155.7 ^INR	+0.19%		-5.15%	+17.95%

27/06	Wanbury Gets INR600 Million Term Loan from Tata Capital	MT
27/06	Wanbury Limited Receives Term Loan Facilities from Tata Capital Limited	CI

Wanbury Limited Receives Term Loan Facilities from Tata Capital Limited

June 27, 2024 at 02:28 pm IST

Wanbury Limited announced that the company has received a term loan facilities of INR 600 million from Tata Capital Limited, at 12.50 % interest per annum repayable over a period of seven years.

Latest news about Wanbury Limited

Wanbury Gets INR600 Million Term Loan from Tata Capital	27/06	MT
Wanbury Limited Receives Term Loan Facilities from Tata Capital Limited	27/06	CI
US FDA Clears Wanbury's Patalganga, India Site; Shares Climb 4%	18/06	MT
Wanbury Limited Announces Retirement of Narinder Kumar Puri as Independent Director	01/04	CI
Wanbury Limited Announces Retirement of Pallavi Prakash Shedge as Independent Director	21/02	CI
Wanbury Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	24/01	CI
Wanbury Limited Approves Appointment of Pravin Dilip Pawar as the Non-Executive Independent Director	18/11	CI
Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	20/23/20	CI
Wanbury Limited announced that it expects to receive INR 60 million in funding from Expert Chemicals Pvt. Ltd.	20/23/20	CI
Wanbury Limited Appoints Mohan Kumar Rayana as Whole Time Director	21/23/21	CI
Wanbury Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Wanbury Limited Approves Issue of Unlisted, Secured Redeemable, Non-Convertible Debentures	11/23/11	CI
Wanbury Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	07/23/07	CI
Wanbury Limited Announces Board Changes	27/23/27	CI
Wanbury Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Wanbury Widens Loss in Fiscal Q2	29/22/29	MT
Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	28/22/28	CI
Wanbury Limited Auditor Raises 'Going Concern' Doubt	06/22/06	CI
Wanbury Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/22/10	CI
Wanbury Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	22/22/22	CI
Wanbury Limited Approves Appointment of Non-Executive Independent Directors	17/22/17	CI
Wanbury Limited Approves Board Appointments	17/22/17	CI
Wanbury Limited announced that it expects to receive INR 143.0625 million in funding from Expert Chemicals Pvt. Ltd.	17/22/17	CI
Wanbury Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	08/22/08	CI
Wanbury Limited Announces the Demise of S. K. Bhattacharyya, from the Board of Directors and Committees	27/22/27	CI

Wanbury Limited is an India-based pharmaceutical company having a presence in active pharmaceutical ingredients (APIs) global market and domestic branded formulations. It is engaged in the business of pharmaceutical and related activities, including research. Its API products include metformin, metformin dc, tramadol, sertraline, diphenhydramine hcl, diphenhydramine citrate, mefenamic acid, paroxetine hemihydrate, promethazine, glucosamine, clopidogrel, levetiracetam and carvedilol phosphate monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on development of products like ketamine, rivaroxaban, montelukast, sitagliptin and few others to reduce dependency on metformin and sertraline. The Company has USFDA and EUGMP approved facilities at Tanuku, Andra Pradesh, and Patalganga, Maharashtra.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
WANBURY LIMITED	+17.95%	61.16M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.76%	43.77B
OTSUKA HOLDINGS CO., LTD.	+28.00%	22.83B
SANDOZ GROUP AG	+20.25%	15.56B
CIPLA LIMITED	+18.82%	14.34B
ZYDUS LIFESCIENCES LIMITED	+55.83%	12.96B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.70%	6.41B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.69B